Latest Naloxone Stories
President and CEO Mark A. Sirgo Describes BUNAVAIL(TM) Delivery, Competitive Advantages, Market Size and Patient Need RALEIGH, N.C., June 11, 2014 /PRNewswire/ -- Dr. Mark A.
RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A.
A nasal-spray version of Naloxone, a heroin/opiate overdose-reversal drug, is in the works in Kentucky. (PRWEB) June 06, 2014 As reported by USA Today
First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S.
RICHMOND, Va., May 19, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) announced today that it has entered into a definitive agreement with AntiOp, Inc.
BUNAVAIL PDUFA date June 7, 2014; Pre-launch activities underway to support an anticipated late Q3 2014 launch RALEIGH, N.C., May 8, 2014 /PRNewswire/ -- BioDelivery Sciences International,
Passages Malibu CEO comments on enhanced access to treatment in the US. Malibu, CA (PRWEB) May 06, 2014
The auto-injector is designed to allow quick administration when drug overdose first occurs. LOS ANGELES, CA (PRWEB) April 09, 2014 Family members and
The auto-injector is designed to allow quick administration when drug overdose first occurs LOS ANGELES, April 8, 2014 /PRNewswire/ -- Family members and caregivers of individuals
First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International,
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.